The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 594-599

  LeBlanc, Rona A ^a   Pesnicak, Lesley ^a   Godleski, Matthew ^a   Straus, Stephen E ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b 10 Center Dr ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; VALACICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS LATENCY; VIRUS VIRULENCE;

2-AMINOPURINE; ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; BRAIN; CERCOPITHECUS AETHIOPS; EYE; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MICE; MICE, INBRED BALB C; PRODRUGS; TRIGEMINAL GANGLION; VALINE; VERO CELLS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 0032827042     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314962     Document Type: Article

References (29)

1. 1. Whitley R. Herpes simplex viruses. In: Fields BN, Knipe DM, eds. Fields virology. New York: Raven Press, 1990:1843-87.
2. 2. Sawtell NM, Thompson R. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J Virol 1992;66:2150-6.
3. 3. Laycock KA, Lee SF, Brady RH, Pepose JS. Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Invest Ophthalmol Vis Sci 1991;32:2741-6.
4. 4. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes: relation to HSV type and antibody response. N Engl J Med 1981;305:315-9.
5. 5. Oakes J. Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection. Infect Immun 1975;12:166-72.
6. 6. Nash AA, Cambouropoulos P. The immune response to herpes simplex virus. Semin Virol 1993;4:181-6.
7. 7. Nash AA, Field H, Quartey-Papafio R. Cell-mediated immunity in herpes simplex virus infected mice: induction, characterization and antiviral effects of delayed-type hypersensitivity. J Gen Virol 1980;48:351-7.
8. 8. Lekstrom-Hines JA, Pesnicak L, Straus SE. The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol 1998;72:2760-4.
9. 9. Beutner K. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995;28:281-90.
10. 10. Boyd MR, Bacon T, Sutton D. Antiherpes activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother 1988;32:358-63.
11. 11. Boyd MR, Safrin S, Kern BR. Penciclovir: a review of its spectrum of activity, selectivity and cross-resistance pattern. Antiviral Chem Chemother 1993:4(Suppl 1):3-11.
12. 12. Earnshaw DL, Bacon T, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge RA. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type I (HSV-1), HSV-2 and varicella-zoster virus. Antimicrob Agents Chemother 1992;36:2747-57.
13. 13. Perry CM, Faulds D. Valacyclovir a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52:754-72.
14. 14. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993;4(Suppl I):47-55.
15. 15. Stein G. Pharmacology of new antiherpes agents: famciclovir and valacyclovir. J Am Pharm Assoc (Wash) 1997;NS37:157-63.
16. 16. Sutton D, Kern B. Activity of famciclovir and penciclovir in HSV-infected animals: a review. Antiviral Chem Chemother 1993;4(Suppl 1):37-46.
17. 17. Thackray AM, Field HJ. Differential effects of famciclovir and valacyclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J Infect Dis 1996;173:291-9.
18. 18. Thackray AM, Field HJ. Comparison of effects of famciclovir and valacyclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob Agents Chemother 1996;40:846-51.
19. 19. Thackray AM, Field HJ. Famciclovir and valacyclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study. Antimicrob Agents Chemother 1998;42:1555-62.
20. 20. Field HJ, Tewari D, Sutton D, Thackray AM. Comparison of efficacies of famciclovir and valacyclovir against herpes simples virus type 1 in a murine immunosuppression model. Antimicrob Agents Chemother 1995;39: 1114-9.
21. 21. Challberg M. A method for identifying the viral genes required for herpesvirus DNA replication. Proc Natl Acad Sci USA 1986;83:9094-8.
22. 22. Goldin AL, Sandri-Goldin R, Levine M, Glorioso JC. Cloning of herpes simplex virus type1 sequences representing the whole genome. J Virol 1981;38:50-8.
23. 23. Field HJ, Bell SB, Elion GB, Nash AA, Wildy P. Effects of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother 1979;15:554-61.
24. 24. Straus SE, Smith HA, Brickman C, de Miranda P, McLaren C, Keeney RE. Acyclovir for chronic mucocutaneous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med 1982;96:270-7.
25. 25. Tyring SK, Douglas J, Corey L, Spruance SL, Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 1998;134:185-91.
26. 26. Wutzler P, Ulbricht A, Farber I. Antiviral efficacies of famciclovir, valacyclovir and brivudin in disseminated herpes simples virus type 1 infection in mice. Intervirology 1997;40:15-21.
27. 27. Maggionealda J, Mehta A, Su YH, Fraser NW, Block TM. Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia. Virology 1996;225:72-81.
28. 28. Sawtell N. The probability on in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol 1998;72:6888-92.
29. 29. Sawtell NM, Poon D, Tansky CS, Thompson RL. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J Virol 1998;72:5343-50.